exemestan actavis film coated tablet 25mg - search results

arrotex pharmaceuticals pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

nolvadex-d tamoxifen 20mg (as citrate) tablet blister pack

astrazeneca pty ltd - tamoxifen citrate, quantity: 30.4 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; lactose monohydrate; gelatin; titanium dioxide; maize starch; macrogol 300; hypromellose; magnesium stearate - treatment of breast cancer nolvadex-d is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex-d is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

exemestane 25mg tablets

morningside healthcare ltd - exemestane - oral tablet - 25mg

Australia - English - Department of Health (Therapeutic Goods Administration)

nolvadex tamoxifen 10mg (as citrate) tablet blister pack

astrazeneca pty ltd - tamoxifen citrate, quantity: 15.2 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; gelatin; hypromellose; macrogol 300; lactose monohydrate; maize starch; magnesium stearate; titanium dioxide - treatment of breast cancer nolvadex is indicated for the treatment of breast cancer. primary reduction of breast cancer risk nolvadex is indicated for the primary reduction of breast cancer risk in women either at moderately increased risk (lifetime breast cancer risk 1.5 to 3 times the population average) or high risk (lifetime breast cancer risk greater than 3 times the population average).